MG
CAMP icon

Michael Gelband’s CAMP4 Therapeutics CAMP Stock Holding History

Michael Gelband’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,720
Closed -$213K – 1591
2025
Q4 		$213K Buy
+34,720
New +$148K ﹤0.01% 1379

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's CAMP Position: Q1 2026 in Review

Michael Gelband sold out of CAMP4 Therapeutics (CAMP) in Q1 2026, closing a stake of 34,720 shares — an estimated $213K sold.

Michael Gelband first reported a position in CAMP in Q4 2025 and held it in 1 quarter. The position peaked at $213K in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Michael Gelband reported no remaining CAMP4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 34,720 CAMP4 Therapeutics shares in Q1 2026, an estimated $213K.
  • Michael Gelband first reported a position in CAMP4 Therapeutics in Q4 2025 and held it in 1 quarter.
  • Michael Gelband's CAMP4 Therapeutics position peaked at $213K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.